KALVHIGH SIGNALREGULATORY10-K

KalVista Pharmaceuticals successfully transitioned from a clinical-stage company to a commercial biopharmaceutical company with FDA approval of EKTERLY, the first oral on-demand therapy for hereditary angioedema.

This represents a fundamental business transformation, as the company moved from pre-revenue drug development to having an approved, first-in-class therapy that addresses a significant unmet medical need. The FDA approval of EKTERLY positions KalVista to begin generating revenue from what could be a substantial market opportunity in the rare disease space, particularly given the drug's unique oral delivery mechanism compared to existing injectable treatments.

Comparing 2025-07-10 vs 2024-07-11View on EDGAR →
FINANCIAL ANALYSIS

The financial picture reflects the high cash burn typical of a biotech company preparing for commercial launch, with operating cash flow substantially higher in the negative direction and net losses meaningfully increased. Current liabilities roughly doubled while stockholders' equity declined significantly, indicating substantial cash consumption during the period leading up to and following FDA approval. R&D expenses modestly decreased, likely reflecting the completion of the pivotal KONFIDENT trial and transition toward commercial preparation activities.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+98%
$22.8M→$45.2M

Current liabilities surged 98% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-71.4%
-$89.2M→-$152.9M

Operating cash flow fell 71.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-53.8%
$206.6M→$95.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-44.9%
-$126.6M→-$183.4M

Net income declined 44.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-33.9%
-$140.4M→-$188.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
-33.6%
$11.3M→$7.5M

Liabilities reduced 33.6% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-16.8%
$86.2M→$71.7M

R&D spending cut 16.8% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2025-07-10
PRIOR — 2024-07-11
ADDED
Overview Our Company We are a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs.
Food and Drug Administration (the FDA ) approved our new drug application ( NDA ) for the use of EKTERLY (sebetralstat), a novel, orally delivered, small molecule plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema ( HAE ) in adult and pediatric patients aged 12 years and older.
EKTERLY (sebetralstat) is the first and only oral, on-demand therapy for HAE.
The efficacy and safety of EKTERLY was established by the results from the phase 3 KONFIDENT clinical trial, published in the New England Journal of Medicine in May 2024.
Based on data from KONFIDENT, together with confirmatory evidence from pharmacokinetic/pharmacodynamic studies, the 600 mg dose of EKTERLY (sebetralstat) was considered by the FDA to be the optimal dose and included in the approved labeling.
The KONFIDENT clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile.
HAE attacks treated with 600 mg of sebetralstat achieved the primary endpoint of beginning of symptom relief significantly faster than placebo (p=0.0013 ) with a median time to beginning of symptom relief of 1.79 hours (CI 1.33, 2.27) as compared to 6.72 hours with placebo (CI 2.33, 12).
Consistent with previous studies, sebetralstat was well-tolerated, with a safety profile similar to placebo.
There were no patient withdrawals due to any adverse event and no treatment-related serious adverse events (SAEs) were observed.
Treatment-related adverse event rates were 2.2% for 600 mg sebetralstat as compared to 4.8% for placebo.
REMOVED
Overview We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need.
We have used our capabilities to develop sebetralstat, a novel, small molecule plasma kallikrein inhibitor targeting the disease hereditary angioedema ( HAE ).
In June 2024, we announced that we have filed a New Drug Application ( NDA ) with the U.S.
Food and Drug Administration ( FDA ) seeking marketing approval of sebetralstat as the first oral, on-demand therapy for HAE.
We also are conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
HAE is a rare and potentially life-threatening, genetically-driven disease that features episodes of debilitating and often painful swelling in the skin, gastrointestinal tract or airways.
Although multiple therapies have been approved for the disease, we believe people living with HAE are in need of alternatives that better meet their objectives for quality of life and ease of disease control.
Other than one oral therapy approved for prophylaxis, currently marketed therapies are all administered by injection, which patients find challenging despite their efficacy because they are painful, time consuming to prepare and administer, and difficult to transfer and store.
As a result, many attacks are treated too late to prevent significant symptoms, and a large percentage aren t treated at all, leading to needless suffering.
We anticipate that there will be strong interest in a safe and effective, orally delivered on-demand treatment, which would provide patients a new and compelling option with which to treat their disease.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →